Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
BackgroundHigh‐flow nasal cannula (HFNC) therapy is a non‐invasive respiratory treatment characterized by high tolerability, which largely derives from the patient's comfort.AimsThe primary aim of this study was to explore whether the patient's perceived comfort was the same regardless of different approaches used to reach the target humidification temperature. The secondary aim was to assess the patient's perceived nasal dryness and humidity.Study DesignThis single‐centre, pragmatic, randomized trial was registered at clinicaltrials.gov (NCT05688189). Patients in the intensive care unit (ICU) in need of HFNC therapy were randomly assigned to one of three study arms: a two‐step increase (31 to 34 to 37°C), a one‐step increase in temperature (34–37°C) or no temperature increase (started and remained at 37°C). The patients were asked to rate their perceived comfort, as well as their perceived nasal dryness and humidity on a scale from 1 (lowest value) to 5 (highest value).ResultsWe enrolled 21 patients, aged 34–85 years. The mean (±1 standard deviation) comfort level was 3.3 (1.3) for patients who received a one‐step increase, 3.1 (1.3) for those who received no increase and 2.7 (1.7) for those who received a two‐step increase (p = .714). There was also no difference in nasal dryness (p = .05) or humidity (p = .612) across the study arms. Greater comfort was fairly correlated with less nasal humidity (ρ = −0.34, 95% confidence interval −0.68 to 0.07) but not with nasal dryness (ρ = 0.01, p = .94).ConclusionsAfter 30 min of HFNC therapy at a target temperature of 37°C, overall comfort was rated similarly in the three study arms. Additional studies are needed to accumulate evidence corroborating the findings of this study.Relevance to Clinical PracticeThe temperature of the mixture of air and oxygen is a fundamental component of HFNC therapy. A pragmatic approach irrespective of the initial temperature setting seems to yield a similar comfort score in hospitalized patients with mild respiratory failure because of extrapulmonary causes.
BackgroundHigh‐flow nasal cannula (HFNC) therapy is a non‐invasive respiratory treatment characterized by high tolerability, which largely derives from the patient's comfort.AimsThe primary aim of this study was to explore whether the patient's perceived comfort was the same regardless of different approaches used to reach the target humidification temperature. The secondary aim was to assess the patient's perceived nasal dryness and humidity.Study DesignThis single‐centre, pragmatic, randomized trial was registered at clinicaltrials.gov (NCT05688189). Patients in the intensive care unit (ICU) in need of HFNC therapy were randomly assigned to one of three study arms: a two‐step increase (31 to 34 to 37°C), a one‐step increase in temperature (34–37°C) or no temperature increase (started and remained at 37°C). The patients were asked to rate their perceived comfort, as well as their perceived nasal dryness and humidity on a scale from 1 (lowest value) to 5 (highest value).ResultsWe enrolled 21 patients, aged 34–85 years. The mean (±1 standard deviation) comfort level was 3.3 (1.3) for patients who received a one‐step increase, 3.1 (1.3) for those who received no increase and 2.7 (1.7) for those who received a two‐step increase (p = .714). There was also no difference in nasal dryness (p = .05) or humidity (p = .612) across the study arms. Greater comfort was fairly correlated with less nasal humidity (ρ = −0.34, 95% confidence interval −0.68 to 0.07) but not with nasal dryness (ρ = 0.01, p = .94).ConclusionsAfter 30 min of HFNC therapy at a target temperature of 37°C, overall comfort was rated similarly in the three study arms. Additional studies are needed to accumulate evidence corroborating the findings of this study.Relevance to Clinical PracticeThe temperature of the mixture of air and oxygen is a fundamental component of HFNC therapy. A pragmatic approach irrespective of the initial temperature setting seems to yield a similar comfort score in hospitalized patients with mild respiratory failure because of extrapulmonary causes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.